VascularStrategies was founded in 2006. Founding board members Dr. Steven Adelman, Dr. Daniel Rader and Dr. George Rothblat had a vision for providing research and development services to pharmaceutical companies that went beyond the capabilities of their academic labs and those of existing CRO companies.
During this time, VascularStrategies moved into 1000 sq. ft. of laboratory space in a start-up incubator at the Lankenau Institute of Medical Research in Wynnewood, PA. The company began consulting with pharmaceutical companies to support drug development with a focus on cell-based functional assays of HDL metabolism, as well as in vivo studies of lipoprotein metabolism and atherosclerosis. In 2010, the company expanded into regulatory compliant GMP and GLP services to meet the needs of our clients.
In 2012, to better meet our needs of our clients, VascularStrategies increased its capabilities by moving into 6,000 sq. ft. of renovated research and office space in Plymouth Meeting, PA, thus allowing the company to expand both technical staff and equipment resources for both cell-based functional assays and in vivo services. More recently in 2016, VascularStrategies added additional laboratory and sample storage space to keep up with the growing demand for research services.
Our commitment to evolving to meet our clients’ needs has become a core business of the company. While our therapeutic focus is cardiovascular disease, we are continually expanding our biomarker and research services support across a wide range of therapeutic areas, including inflammation, nutrition and neurologic disorders.